Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...

Bristol-Myers Squibb ( ($BMY) ) has shared an announcement. On November 3, 2025, Bristol-Myers Squibb announced the ...

Bristol-Myers' growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines. Read why BMY ...

Bristol Myers Squibb (BMY) just reported new 52-week Phase 3 trial results for Sotyktu in adults with active psoriatic ...

CHONGQING, CHINA - APRIL 20: In this photo illustration, the Bristol Myers Squibb logo is displayed on a smartphone screen, with the company's signature purple branding in the background, on April 20, ...

Bristol-Myers Squibb Company remains a solid, cash-generative blue-chip stock, with expected slow growth & patience. Learn ...

Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported third quarter EPS of $1.63, $0.11 better than the analyst estimate of $1.52. Revenue for the quarter came in at $12.2B versus the consensus ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 7.14x forward earnings, lower than its ...

The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Analysts are estimating that Bristol-Myers Squibb will report an earnings per share (EPS) of $1.51. The market awaits Bristol ...